Sun Pharmaceutical Industries Limited

Sun Pharma Advanced Research Company Limited

Pharmaceutical Industries Limited

Sun Pharmacuetical Industries Ltd.

Sun Pharmaceutical Indsutries Ltd.

Subhas Balaram Bhowmick

Prashant Kane

Samarth Kumar

Maheshkumar Parasmal Soni

Sudeep Kumar Agrawal

Kirti Ganorkar

Rajamannar Thennati

Ajay Khopade

Nishit Patel

Amar Rana

Ramaji Karshanbhai Varu

Nisarg Bipinchandra Mistry

Satyashodhan Babasaheb Patil

Deepak Singodia

Natarajan Arulsudar

Bhaskar Pallerla

Rakesh Thummar

Praveen Kumar Srivastava

Raman Lad

Sapna Fadnis

Milan Mohanbhai Vasoya

Mark Hagler

Shantaram Pawar

Kartik Nagar

Alpesh Goyani

Arindam Halder

Milan Natvarbhai Thakkar

Kandarp Maheshkumar Dave

Alex George

Alok B Namdeo

Swapnil Ramesh Patil

Abhijit Takale

Simon James Smith

David Stuart Harris

Satish Madhukar Gokhale

Richard Francis Day

Lee Wood

Lynne Bui

Jonathan Wilkins

Duncan Aleck Bishop

Wen Wee Ma

Madhusudhan Bommagani

Vaibhav Dubey

Alex Adjei

Narayanaswamy Subramanian

Jonathan Hugh Wilkins

Ganesh Sangaiah

Ajay Nandgaonkar

Ronald Harning

Samantha Anne Musgrave

Becky Lynn Pilditch

Matthew David Allen

Ashish Anilrao Dubewar

Soni Maheshkumar Parasmal

Umeshkumar Mukeshbhai Patel

Narendra Lakkad

Jaydip Joshi

Arunkumar Yadav

Ramaji Karshanbhai Mistry

Ajay Jaysingh Khopade

N Arulsudar

A parenteral dosage form having an infusion container filled with an aqueous solution in volumes ranging from 40 ml to 500 ml comprising 1 mg/ml to 2 mg/ml of carboplatin, wherein the solution contains known impurity of 1, 1-cyclobutanedicarboxylic acid in an amount of not more than 1.0% by weight of carboplatin and the solution remains physically stable when stored at room temperature.

Parenteral dosage form of carboplatin

The present invention refers to an intravenous infusion dosage form comprising a composition containing pemetrexed or its pharmaceutically acceptable salt, an osmagent and an aquous vehicle. The composition is present in a flexible infusion container containing an inert gas in the headspace. Additionally, a second container may be present surrounding the flexible infusion container.

Intravenous infusion dosage form

A method of providing and/or injecting octreotide acetate to a subject in need thereof includes storing the octreotide acetate in a cartridge of a multi-use multi-dose injector provided with a variable dose setter and actuator. The injector includes a needle configured for subcutaneous administration of the octreotide acetate, the octreotide acetate having a concentration of 2,500 μg/mL. The method further includes permitting setting of a dose of the octreotide acetate by rotation of the variable dose setter. The injector is configured to provide at least one audible feedback during the rotation. The method further includes operating the actuator to deliver the octreotide acetate from the cartridge through the needle to treat the subject. The injector is provided with multiple surface portions.

Method of injecting octreotide acetate into the body

The present invention relates to a dosage form comprising an aqueous solution of a vinca alkaloid drug or its pharmaceutically acceptable salt in a flexible infusion container, and a light protective secondary packaging containing the flexible infusion container, wherein the dosage form is ready-to-infuse and wherein the aqueous solution is stable at room temperature.

Dosage form of vinca alkaloid drug

The present invention provides a ready to use stable aqueous dosage form of norepinephrine comprising an aqueous solution of norepinephrine or its pharmaceutically acceptable salt, one or more sulfite antioxidants and an ion chelator. The present invention also provides an infusion container filled with an aqueous solution of norepinephrine or its pharmaceutically acceptable salt, wherein the said solution is stable for a prolonged period of time and can be terminally sterilized by autoclaving.

Infusion dosage form of norepinephrine

A perfusion container for directly administering to patients a dose of an antineoplastic drug calculated according to a patient's parameter, wherein the first perfusion container comprises a solution of antineoplastic drug at a concentration and volume such that the amount of antineoplastic drug in the container is equal to the calculated dose for one patient but less than the calculated dose for a second patient, the calculated dose is provided to first patient within 5% variance by directly administering the full volume of the solution of antineoplastic drug from the first perfusion container, further the first perfusion container is accompanied by a second top-up perfusion container comprising a solution of antineoplastic drug at a concentration and volume such that the calculated dose is provided within 5% variance by directly administering the full volume of the solution of antineoplastic drug from the first perfusion container and the second top-up container to the second patient.

Perfusion system

The invention relates to an infusion container comprising a sterile, ready-to-use, stable aqueous solution of Midazolam or a pharmaceutically acceptable salt thereof, suitable for direct intravenous infusion to a patient in need thereof. The invention also relates to a novel infusion container having plurality of ports that is suitable for delivering or receiving a sterile fluid, such as the said stable aqueous solution of Midazolam or a pharmaceutically acceptable salt thereof.

Infusion bag of Midazolam for intravenous use

A parenteral unit dosage form comprising an aqueous solution of dihydroergotamine or pharmaceutically acceptable salt thereof as a sole active ingredient, one or more pH adjusting agents, and optionally one or more co-solvents, wherein the pH of the aqueous solution is such that it contains substantially lower amount of impurity of Formula I and impurity of Formula II as compared to aqueous solution having a pH of 4.0 or less, when the parenteral unit dosage form is stored at 25&#xb0; C. and 60% relative humidity for at least three months.

Parenteral unit dosage form of dihydroergotamine

The present invention relates to a method for enabling hospitals or clinics to administer a dose of a drug to patients in need thereof while avoiding steps of manipulation, dilution, reconstitution, dispensing, sterilization, transfer, handling or compounding before intravenous administration. The present invention further relates to a perfusion system comprising different sets of perfusion containers, each container comprising a ready-to-infuse, stable, sterile, aqueous perfusion solution of a drug, wherein the set of perfusion containers alone or in combination provides for direct intravenous administration of a desired dose of the drug to a patient in need thereof, such that the delivered dose is equal to or within &#xb1;5% of the calculated dose.

Perfusion dosage form

A method of providing and/or injecting octreotide acetate to a subject in need thereof includes storing the octreotide acetate in a cartridge of a multi-use multi-dose injector provided with a variable dose setter and actuator. The injector includes a needle configured for subcutaneous administration of the octreotide acetate, the octreotide acetate having a concentration of 2,500 &#x3bc;g/mL. The method further includes providing, on the injector, a plurality of indicia only at prescribed doses of 50 &#x3bc;g, 100 &#x3bc;g, 150 &#x3bc;g and 200 &#x3bc;g settable via the dose setter without indicia between said prescribed doses; and permitting setting of a dose of the octreotide acetate by rotation of the variable dose setter, wherein the injector is configured to provide at least one audible feedback during the rotation.

A method of treating patients suffering from carcinoma of intrahepatic or extra hepatic bile duct or gall bladder which is locally advanced or metastatic, by intravenously administering to the patient, paclitaxel in the form of a nanodispersion. The nanodispersion comprises particles with a mean particle size less than 300 nm and is free of polyoxyethylated castor oil and free of a protein.

Method of treating carcinoma

A parenteral unit dosage form comprising an aqueous solution of dihydroergotamine or pharmaceutically acceptable salt thereof as a sole active ingredient, one or more pH adjusting agents, and optionally one or more co-solvents, wherein the pH of the aqueous solution is such that it contains substantially lower amount of impurity of Formula I and impurity of Formula II as compared to aqueous solution having a pH of 4.0 or less, when the parenteral unit dosage form is stored at 25&#xb0; C. and 60% relative humidity for at least three months. 

Infusion bag of midazolam for intravenous use

Growing community of inventors

Baroda, India

Subhas Balaram Bhowmick